Intelligent Bio Solutions

Fingerprint drug tests offer a non-invasive and dignified alternative to traditional urine and saliva drug tests.

The page compares Intelligent Fingerprinting’s drug testing solution with urine and saliva screening methods.

The Saliva Glucose Biosensor is a favorable solution to finger-prick blood glucose testing when monitoring diabetes.

INBS (Intelligent Bio Solutions) Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results.

Intelligent Bio Solutions (INBS) Commences Multi-Site Method Comparison Study for FDA 510(k) Submission to validate accuracy and performance.

Goldstar Transport, the UK’s market-leading container haulier, has switched out urine tests for fingerprint drug testing.

Intelligent Bio Solutions is a medical technology company that provides rapid, non-invasive testing solutions.

The contact page lists addresses in New York, NY, and Barangaroo, NSW, and the email info@ibs.inc.

Intelligent Bio Solutions (INBS) provides non-invasive, real-time point-of-care testing solutions.

The privacy policy describes how the company collects, stores, uses, manages, and discloses personal information.

Intelligent Bio Solutions submits an FDA 510(k) clearance application for its **Intelligent Fingerprinting Drug Screening System**. The submission includes a **Method Comparison Study** showing **>98% accuracy**, **>94% sensitivity**, and **100% specificity** across three test categories. The company now seeks U.S. market approval for its drug screening technology.

Sep 2026GlobeNewswireNews article

Intelligent Bio Solutions reports **above 98% accuracy** in a method comparison study for its diagnostic tool. The results support the company’s **planned 2026 FDA 510(k) submission**, a key regulatory milestone for commercializing its technology. The study validates performance against established benchmarks in clinical diagnostics.

Sep 2026Intelligent Bio Solutions Inc.News article

Intelligent Bio Solutions raises up to **$15 million** in a private placement from an existing institutional investor, priced at-the-market under Nasdaq rules. The deal includes a **$5 million upfront payment** at closing and a **$5 million tranche** contingent on FDA **510(k) clearance** for its *Intelligent Fingerprinting Drug* platform. The remaining **$5 million** is tied to a warrant callable by the company post-approval.

Sep 2026GlobeNewswireNews article

Intelligent Bio Solutions achieves **38% year-over-year revenue growth** in fiscal 2026, fueled by a **22% expansion in its reader installed base** and a **35% rise in consumable cartridge sales**, exceeding **100,000 units**. The company’s high-margin cartridge segment contributes significantly to its financial performance.

Aug 2026GlobeNewswireNews article